Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart

Lisata laid off 72% of its staff and is suing Kuva Labs after a planned acquisition deal collapsed, forcing Lisata to seek alternative strategies to preserve cash. The aborted merger and lawsuit highlight serious challenges for Lisata’s solid tumor drug development.

This Wire brief sits within Fusion42's coverage of Biotech.